Breast Cancer Study of Clinical Efficacy and Safty of Avastin with Paclitaxel in the 1st-taxane-line
Phase 2
- Conditions
- HER2-negative metastatic breast cancer
- Registration Number
- JPRN-UMIN000007948
- Lead Sponsor
- Hiroshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Forbidden case to use paclitaxel and bevacizumab. (2) With uncontrollable hypertension. (3) Nonhealing wound. (4) With VTE or PE. (5) With GI perforation or Digestive ulcer. (6) Severe cardiac disease (Ex. Congestive heart failure or coronary artery disease)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method